PUS7L

Across TCGA pan-cancer cohorts, PUS7L RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of PUS7L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PUS7L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PUS7L is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, BLCA, and KIRP are the cancer types where PUS7L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PUS7L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.427	<.001	11	view →
BLCA	Female	All	+0.703	<.001	10	view →
KIRP	All	II,III,IV	+0.615	.004	10	view →
LIHC	Female	II,III,IV	+0.830	<.001	8	view →
THCA	Male	II,III,IV	−0.816	<.001	8	view →
COAD	Male	All	+0.759	<.001	8	view →
HNSC	All	All	+0.392	<.001	8	view →
LUAD	Male	All	+0.873	<.001	7	view →
STAD	All	II,III,IV	+0.729	<.001	7	view →
LUSC	Male	II,III,IV	+0.629	<.001	6	view →
BRCA	All	II,III,IV	+0.425	<.001	6	view →
CHOL	Male	All	+1.631	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

PUS7L–KIRC

Open the KIRC breakdown →